Dr. Fonge is the President & CEO of ACT225 BioTx and a full Professor at Université Laval. He is a Canada Research Chair – Tier 1 in “Radiopharmacy and Translational Cancer Theranostics”. Dr. Fonge completed his PhD in radiopharmacy from KU Leuven (Leuven, Belgium) and postdoctoral studies from the University of Toronto (Toronto Canada). He also completed an MBA from the University of Toronto’s Rotman’s School of Business with specialization in business strategy and commercialization of life sciences innovations. His lab engages in bench to bed research of novel theranostics and has been a co-PI on four clinical trials. He has also completed informal training on many aspects of research translation including good manufacturing practice (GMP) and good clinical practice (GCP) and has several years’ experience as a scientific reviewer of Research Ethics Board (REB). Dr. Fonge is the inventor of many IPs on cancer theranostics.